Today: October 5, 2015, 6:07 am

PHARMACYCLICS - Ibrutinib - Promising to Deliver More - new market research report published
PHARMACYCLICS - Ibrutinib - Promising to Deliver More - a new market research report on 2014-03-14 09:10:03
Our risk-reward analysis suggests that there is meaningful upside on positive PhIII data and approval of Ibrutinib (PCI-32765, PhIII, BTK inhibitor, partnered with JNJ, PhIII, CLL/SLL/PLL, MCL; PhII, DLBCL, MM, FL) in next two years.

Ibrutinib, a winner in the making - oral, once-daily dosing, high degree of B-cell specificity, has demonstrated remarkable efficacy and safety profile:

i) Tumor reduction (response) in heavily pretreated pts,

ii) Responses in pts previously treated with chemotherapy and with aggressive disease,

iii) Durable responses - many pts still on drug after prolonged period of time

iv) Patient tolerability including lack of bone marrow damage.

Ibrutinib is a best-in-class among leukemia drugs, showed durable efficacy in Tx-naïve (TN) and refractory (R/R) CLL and MCL pts as a monotherpay and in combination studies which suggests a mega buster sales potential.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 346 Words
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.